Drug could be repurposed for T-ALL

Print Friendly, PDF & Email


Micrograph showing T-ALL
© Hind Medyouf, German
Cancer Research Center
Venetoclax might improve the treatment of certain patients with T-cell acute lymphoblastic leukemia (T-ALL), according to preclinical research published in Leukemia. Researchers found that a ribosomal defect—the R98S mutation in ribosomal protein L10 (RPL10 R98S)—causes overexpression of BCL-2 in T-ALL. The BCL-2 inhibitor venetoclax induced... [Read Article]
Print Friendly, PDF & Email

Treatment guidelines for CAR T-cell therapy

Print Friendly, PDF & Email


CAR T cells
Photo from Penn Medicine
Researchers have developed treatment guidelines for pediatric patients receiving chimeric antigen receptor (CAR) T-cell therapy. The guidelines include recommendations for patient selection and consent, treatment details, and advice on managing cytokine release syndrome (CRS) and other adverse events associated with CAR T-cell therapy. The guidelines were published in... [Read Article]
Print Friendly, PDF & Email

Adult CCSs report financial hardships

Print Friendly, PDF & Email


I-Chan Huang, PhD
Photo from St. Jude
Children’s Research
Hospital/Peter Barta
Health-related financial hardship is common among adult survivors of childhood cancer, according to a study published in the Journal of the National Cancer Institute. Researchers analyzed more than 2800 long-term childhood cancer survivors (CCSs) and found that 65% had financial challenges related to their... [Read Article]
Print Friendly, PDF & Email

CHMP announces 2 opinions on blinatumomab

Print Friendly, PDF & Email


Vials of blinatumomab
powder and solution
Photo courtesy of Amgen
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has released 2 new opinions regarding blinatumomab (Blincyto). The CHMP recommended expanding the approved use of blinatumomab to include pediatric patients, but the committee also recommended against approving blinatumomab to treat patients with... [Read Article]
Print Friendly, PDF & Email

Treatments, disease affect spermatogonia in boys

Print Friendly, PDF & Email


Male germinal epithelium
showing spermatogonia,
spermatocytes, spermatids,
and spermatozoa
Image from Dreamstime
Alkylating agents, hydroxyurea (HU), and certain non-malignant diseases can significantly deplete spermatogonial cell counts in young boys, according to research published in Human Reproduction. Boys who received alkylating agents to treat cancer had significantly lower spermatogonial cell counts than control subjects or boys... [Read Article]
Print Friendly, PDF & Email

FDA approves biosimilar filgrastim

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). Nivestym is approved to treat patients with nonmyeloid malignancies who are receiving myelosuppressive chemotherapy or undergoing bone marrow transplant, acute myeloid leukemia patients receiving induction or consolidation chemotherapy,... [Read Article]
Print Friendly, PDF & Email

How ALL invades the CNS

Print Friendly, PDF & Email


Micrograph showing ALL
Researchers believe they have solved the mystery of how acute lymphoblastic leukemia (ALL) infiltrates the central nervous system (CNS). Experiments in mice suggested that ALL enters the CNS not by breaching the blood-brain barrier but by evading it. The researchers said they found that expression of the laminin receptor α6 integrin, which... [Read Article]
Print Friendly, PDF & Email

CHMP recommends CAR T for ALL, DLBCL

Print Friendly, PDF & Email


Tisagenlecleucel (Kymriah)
Photo courtesy of Novartis
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of tisagenlecleucel (Kymriah®, formerly CTL019) for 2 indications. According to the CHMP, the chimeric antigen receptor (CAR) T-cell therapy should be approved to treat adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)... [Read Article]
Print Friendly, PDF & Email

Company stops development of eryaspase in ALL

Print Friendly, PDF & Email


Red blood cells
Erytech Pharma said it plans to stop development of eryaspase for acute lymphoblastic leukemia (ALL). This means withdrawal of the European marketing authorization application for eryaspase as a treatment for relapsed and refractory ALL. However, Erytech will continue development of eryaspase as a treatment for certain solid tumor malignancies.... [Read Article]
Print Friendly, PDF & Email

EC grants blinatumomab full approval

Print Friendly, PDF & Email


Vials of blinatumomab powder
and solution for infusion
Photo courtesy of Amgen
The European Commission (EC) has granted a full marketing authorization for blinatumomab (BLINCYTO®) as a treatment for adults with Philadelphia chromosome-negative (Ph-), relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The EC granted blinatumomab conditional authorization for this indication in... [Read Article]
Print Friendly, PDF & Email

Gene signature might identify patients at risk of CAR T-associated neurotoxicity

Print Friendly, PDF & Email


Attendees at 2018 ASCO Annual Meeting
©ASCO/Zach Boyden-Holmes 2018
A specific gene signature might be able to identify patients at risk of CD19 CAR T-cell associated neurotoxicity, according to results of an exploratory analysis presented at the 2018 ASCO Annual Meeting. The analysis, based on bone marrow samples from patients with relapsed/refractory B-cell acute lymphoblastic... [Read Article]
Print Friendly, PDF & Email

Efficacy of KTE-C19 CAR T cells not compromised by prior blinatumomab

Print Friendly, PDF & Email


McCormick Place during ASCO 2018
©ASCO/Rodney White 2018
Prior exposure to blinatumomab does not appear to affect the successful manufacture of KTE-C19 or its efficacy in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). The clinical benefit of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, was preserved regardless of whether patients were exposed to... [Read Article]
Print Friendly, PDF & Email